pioglitazone has been researched along with Astrocytosis in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has been applied to enhance insulin sensitivity." | 7.88 | Oral pioglitazone ameliorates fructose-induced peripheral insulin resistance and hippocampal gliosis but not restores inhibited hippocampal adult neurogenesis. ( Chen, IC; Chen, LW; Fu, MH; Hung, CY; Liu, WC; Tain, YL; Wu, CW; Wu, KLH, 2018) |
| " Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has been applied to enhance insulin sensitivity." | 3.88 | Oral pioglitazone ameliorates fructose-induced peripheral insulin resistance and hippocampal gliosis but not restores inhibited hippocampal adult neurogenesis. ( Chen, IC; Chen, LW; Fu, MH; Hung, CY; Liu, WC; Tain, YL; Wu, CW; Wu, KLH, 2018) |
| "Pioglitazone treatment led to a significant 3% body mass increase." | 2.90 | Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study. ( Cendes, F; Cintra, RM; de-Lima-Júnior, JC; Folli, F; Monfort-Pires, M; Rachid, B; Ramos, CD; Rodovalho, S; Van de Sande-Lee, S; Velloso, LA, 2019) |
| "Pioglitazone treatment extended survival by 13%, and it reduced gliosis as assessed by immunohistochemical staining for CD-40 and GFAP." | 1.33 | Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Chen, J; Kiaei, M; Kipiani, K, 2005) |
| "Pioglitazone or vehicle were i." | 1.33 | The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Zhao, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de-Lima-Júnior, JC | 1 |
| Rodovalho, S | 1 |
| Van de Sande-Lee, S | 1 |
| Monfort-Pires, M | 1 |
| Rachid, B | 1 |
| Cintra, RM | 1 |
| Ramos, CD | 1 |
| Cendes, F | 1 |
| Folli, F | 1 |
| Velloso, LA | 1 |
| Liu, WC | 1 |
| Wu, CW | 1 |
| Tain, YL | 1 |
| Fu, MH | 1 |
| Hung, CY | 1 |
| Chen, IC | 1 |
| Chen, LW | 1 |
| Wu, KLH | 1 |
| Utreras, E | 1 |
| Hamada, R | 1 |
| Prochazkova, M | 1 |
| Terse, A | 1 |
| Takahashi, S | 1 |
| Ohshima, T | 1 |
| Kulkarni, AB | 1 |
| Kiaei, M | 1 |
| Kipiani, K | 1 |
| Chen, J | 1 |
| Calingasan, NY | 1 |
| Beal, MF | 1 |
| Zhao, Y | 1 |
| Patzer, A | 1 |
| Gohlke, P | 1 |
| Herdegen, T | 1 |
| Culman, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)[NCT00690118] | Phase 2 | 219 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to The interim analysis showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pioglitazone and Astrocytosis
| Article | Year |
|---|---|
Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study.
Topics: Adipose Tissue, Brown; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fl | 2019 |
4 other studies available for pioglitazone and Astrocytosis
| Article | Year |
|---|---|
Oral pioglitazone ameliorates fructose-induced peripheral insulin resistance and hippocampal gliosis but not restores inhibited hippocampal adult neurogenesis.
Topics: Administration, Oral; Adult Stem Cells; Animals; Fructose; Gliosis; Hippocampus; Hypoglycemic Agents | 2018 |
Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPARγ agonist improves neuronal loss and early lethality.
Topics: Animals; Apoptosis; Cyclin-Dependent Kinase 5; Cytokines; Disease Models, Animal; Encephalitis; Gene | 2014 |
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Animals; Cell Count; Disease Models, Animal; Di | 2005 |
The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Encephalit | 2005 |